Title of article
Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety
Author/Authors
Michael P. Sch?n، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2008
Pages
6
From page
509
To page
514
Abstract
Efalizumab is a humanized monoclonal antibody directed against the CD11a subunit of the lymphocyte function-associated antigen 1. It has been approved for the treatment of moderate-to-severe plaque psoriasis. Efalizumab has been shown in several clinical
Journal title
Clinics in Dermatology
Serial Year
2008
Journal title
Clinics in Dermatology
Record number
583250
Link To Document